New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC

Change to section 6 - date of revision

Change to section 6 - date of revision

Change to section 6 - date of revision

Change to section 6 - date of revision

Change to section 3 - overdose, missed or forgotten doses

Change to section 4 - how to report a side effect

Change to section 4 - possible side effects

Change to section 6 - date of revision

pil Curatoderm Ointment

tacalcitol monohydrate

Almirall Limited

Updated 22-Feb-18

Document history

Change to section 1 - what the product is

Change to section 1 - what the product is used for

Change to section 2 - driving and using machines

Change to section 2 - pregnancy, breast feeding and fertility

Change to section 2 - use in children/adolescents

Change to section 2 - what you need to know - contraindications

Change to section 2 - what you need to know - warnings and precautions

Change to section 3 - how to take/use

Change to section 4 - how to report a side effect

Change to section 4 - possible side effects

Change to section 5 - how to store or dispose

Change to section 6 - date of revision

Change to section 6 - what the product contains

Improved presentation of PIL

Change to section 3 - overdose, missed or forgotten doses

Change to section 4 - how to report a side effect

Change to section 4 - possible side effects

Change to section 6 - date of revision

pil Boots Cold and Flu Relief with Ibuprofen

ibuprofen, pseudoephedrine hydrochloride

THE BOOTS COMPANY PLC

Updated 22-Feb-18

Document history

Change to section 3 - overdose, missed or forgotten doses

Change to section 4 - how to report a side effect

Change to section 4 - possible side effects

Change to section 6 - date of revision

Change to section 5 - how to store or dispose

Change to section 6 - date of revision

smpc Solaraze

diclofenac sodium

Almirall Limited

Updated 22-Feb-18

Document history

Change to section 5.1 - Pharmacodynamic properties

New PIL for new product

Change to section 4 - how to report a side effect

Change to section 4 - possible side effects

Change to section 6 - date of revision

smpc Infanrix hexa, Powder and suspension for suspension for injection

diphtheria, tetanus, pertussis (acellular), poliomyelitis (inactivated), hepatitis b (rDNA) and haemophilus influenzae type b (Hib) vaccine

GlaxoSmithKline UK

Updated 22-Feb-18

Document history

Change to section 10 - Date of revision of the text

Change to section 4.4 - Special warnings and precautions for use

Change to section 5.1 - Pharmacodynamic properties

smpc Triapin 5mg/5mg prolonged release tablets

felodipine, ramipril

SANOFI

Updated 22-Feb-18

Document history

Change to section 4.3 - Contraindications

Change to section 4.4 - Special warnings and precautions for use

Change to section 4.5 - Interaction with other medicinal products and other forms of interaction

Change to section 4.8 - Undesirable effects - how to report a side effect

Change to section 4.3 - Contraindications

Change to section 4.4 - Special warnings and precautions for use

Change to section 4.5 - Interaction with other medicinal products and other forms of interaction

Change to section 4.8 - Undesirable effects - how to report a side effect

Change to section 4.3 - Contraindications

Change to section 4.4 - Special warnings and precautions for use

Change to section 4.5 - Interaction with other medicinal products and other forms of interaction

Change to section 4.8 - Undesirable effects - how to report a side effect

Change to section 10 - Date of revision of the text

Change to section 2 - Qualitative and quantitative composition

Change to section 4.2 - Posology and method of administration

Change to section 4.3 - Contraindications

Change to section 4.4 - Special warnings and precautions for use

Change to section 4.6 - Fertility, pregnancy and lactation

Change to section 4.8 - Undesirable effects

Change to section 4.8 - Undesirable effects - how to report a side effect

Change to section 5.1 - Pharmacodynamic properties

Change to section 5.2 - Pharmacokinetic properties

Change to section 6.1 - List of excipients

Change to section 6.4 - Special precautions for storage

Change to section 6.6 - Special precautions for disposal and other handling

Change to section 9 - Date of first authorisation/renewal of the authorisation

Change to section 10 - Date of revision of the text

Change to section 2 - Qualitative and quantitative composition

Change to section 4.2 - Posology and method of administration

Change to section 4.3 - Contraindications

Change to section 4.4 - Special warnings and precautions for use

Change to section 4.6 - Fertility, pregnancy and lactation

Change to section 4.8 - Undesirable effects

Change to section 4.8 - Undesirable effects - how to report a side effect

Change to section 5.1 - Pharmacodynamic properties

Change to section 5.2 - Pharmacokinetic properties

Change to section 6.1 - List of excipients

Change to section 6.4 - Special precautions for storage

Change to section 6.6 - Special precautions for disposal and other handling

Change to section 9 - Date of first authorisation/renewal of the authorisation

Change to section 6.2 - Incompatibilities

Change to section 6.2 - Incompatibilities

New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC

pil Lariam 250 mg Tablets

mefloquine hydrochloride

Roche Products Limited

Updated 22-Feb-18

Document history

Change to section 2 - what you need to know - warnings and precautions

Change to section 4 - how to report a side effect

Change to section 6 - date of revision

Change to section 3 - Pharmaceutical form

Change to section 6 - manufacturer

Change to section 6 - manufacturer

pil Clindamycin 150 mg Capsules

clindamycin hydrochloride

Rivopharm UK Ltd

Updated 22-Feb-18

Document history

Change to section 6 - marketing authorisation holder

Change to section 6 - manufacturer

Change to section 6 - what the product looks like and pack contents

pil Clindamycin 300 mg Capsules

clindamycin hydrochloride

Rivopharm UK Ltd

Updated 22-Feb-18

Document history

Change to section 6 - marketing authorisation holder

pil Moxifloxacin 400 mg film-coated tablets.

moxifloxacin hydrochloride

Rivopharm UK Ltd

Updated 22-Feb-18

Document history

Change to section 4 - possible side effects

New PIL for eMC ie a PIL for an existing product but one that is new to the eMC

Change to section 4 - possible side effects

Change to section 6 - date of revision

New PIL for eMC ie a PIL for an existing product but one that is new to the eMC

New PIL for eMC ie a PIL for an existing product but one that is new to the eMC

New PIL for eMC ie a PIL for an existing product but one that is new to the eMC

Change to section 4.3 - Contraindications

Change to section 4.4 - Special warnings and precautions for use

Change to section 4.6 - Fertility, pregnancy and lactation

Change to section 4.8 - Undesirable effects

Change to section 4.8 - Undesirable effects - how to report a side effect

Change to section 1 - what the product is used for

Change to section 2 - interactions with other medicines, food or drink

Change to section 2 - pregnancy, breast feeding and fertility

Change to section 2 - what you need to know - contraindications

Change to section 2 - what you need to know - warnings and precautions

Change to section 3 - how to take/use

Change to section 3 - overdose, missed or forgotten doses

Change to section 4 - how to report a side effect

Change to section 4 - possible side effects

Change to section 5 - how to store or dispose

Change to section 6 - date of revision

Change to section 6 - what the product contains

Improved presentation of PIL

Change to section 1 - what the product is used for

Change to section 2 - interactions with other medicines, food or drink

Change to section 2 - pregnancy, breast feeding and fertility

Change to section 2 - what you need to know - contraindications

Change to section 2 - what you need to know - warnings and precautions

Change to section 3 - how to take/use

Change to section 3 - overdose, missed or forgotten doses

Change to section 4 - how to report a side effect

Change to section 4 - possible side effects

Change to section 5 - how to store or dispose

Change to section 6 - date of revision

Change to section 6 - what the product contains

Improved presentation of PIL

Change to section 7 - Marketing authorisation holder

Change to section 7 - Marketing authorisation holder

Change to section 7 - Marketing authorisation holder

Change to section 7 - Marketing authorisation holder

Change to section 4.8 - Undesirable effects

Change to section 5.1 - Pharmacodynamic properties

Change to section 4.8 - Undesirable effects

Change to section 5.1 - Pharmacodynamic properties

Change to section 4.8 - Undesirable effects

Change to section 5.1 - Pharmacodynamic properties

Change to section 4.8 - Undesirable effects

Change to section 5.1 - Pharmacodynamic properties

Change to section 4.8 - Undesirable effects

Change to section 5.1 - Pharmacodynamic properties

Change to section 4.8 - Undesirable effects

Change to section 5.1 - Pharmacodynamic properties

Change to section 4.8 - Undesirable effects

Change to section 5.1 - Pharmacodynamic properties

Change to section 4.8 - Undesirable effects

Change to section 5.1 - Pharmacodynamic properties